Nuveen LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 299,275 shares of the life sciences company's stock, valued at approximately $23,744,000. Nuveen LLC owned about 0.19% of Illumina at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Freedom Investment Management Inc. raised its stake in Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after buying an additional 101 shares during the last quarter. Moors & Cabot Inc. raised its stake in Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock valued at $465,000 after buying an additional 145 shares during the last quarter. Probity Advisors Inc. raised its stake in Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock valued at $274,000 after buying an additional 224 shares during the last quarter. Xponance Inc. raised its stake in Illumina by 1.0% in the first quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock valued at $2,123,000 after buying an additional 264 shares during the last quarter. Finally, Rakuten Securities Inc. raised its stake in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
ILMN has been the subject of a number of research analyst reports. Evercore ISI increased their price target on Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Barclays increased their price objective on Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a report on Friday, August 1st. Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Wall Street Zen lowered Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, Piper Sandler cut their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $124.58.
Read Our Latest Stock Report on ILMN
Illumina Stock Performance
Shares of NASDAQ:ILMN opened at $100.53 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The business's 50 day moving average price is $97.12 and its 200-day moving average price is $89.34. The firm has a market capitalization of $15.45 billion, a PE ratio of 12.73, a P/E/G ratio of 2.25 and a beta of 1.37. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the company posted $0.36 earnings per share. The business's revenue was down 4.8% on a year-over-year basis. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access